MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Mibefradil dihydrochloride

CAS No. : 116666-63-8

产品活性：Mibefradil dihydrochloride (Ro 40-5967 dihydrochloride) is a calcium channel blocker with moderate selectivity for T-type Ca²⁺ channels (IC₅₀s of 2.7 μM and 18.6 μM for T-type and L-type currents, respectively).

研究领域：Membrane Transporter/Ion Channel  |  Neuronal Signaling

作用靶点：Calcium Channel

In Vitro: Mibefradil dihydrochloride inhibits reversibly the T- and L-type currents with IC₅₀ values of 2.7 and 18.6 μM, respectively. The inhibition of the L-type current is voltage-dependent, whereas that of the T-type current is not. Ro 40-5967 blocks T-type current already at a holding potential of -100 mV At a higher concentration (20 µM), Mibefradil reduces the amplitude of excitatory junction potentials (by 37±10 %), slows the rate of repolarisation (by 44±16 %) and causes a significant membrane potential depolarisation (from −83±1 mV to −71±5 mV). At a higher Mibefradil concentration (20 µM) there is significant membrane potential depolarisation and a slowing of repolarisation. These actions of Mibefradil are consistent with K⁺ channel inhibition, which has been shown to occur in human myoblasts and other cells.

In Vivo: The hearing thresholds of the 24-26 week old C57BL/6J mice differ following the 4-week treatment period. The hearing threshold at 24 kHz is significantly decreased in the Mibefradil-treated and benidipine-treated groups compared with the saline-treated group (P<0.05). Compared with the saline-treated group, rats receiving Mibefradil or NSC 64013 show significant lower Ca_V3.2 expression in the spinal cord and DRG.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Membrane Transporter/Ion Channel Compound Library  |  Neuronal Signaling Compound Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  Drug Repurposing Compound Library  |  Anti-Cardiovascular Disease Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Neuroprotective Compound Library  |  Rare Diseases Drug Library  |  Calcium Channel Blocker Library  |  FDA-Approved Anticancer Drug Library  |  Off-patent Drug Library  |  Antihypertensive Compound Library  |  Membrane Protein-targeted Compound Library  |  Membrane Receptor-targeted Compound Library  |  Benidipine hydrochloride  |  Isotachysterol 3  |  IAA65  |  Ranolazine-d₈ (dihydrochloride)  |  Diltiazem hydrochloride  |  Palmitoylglycine  |  Lercanidipine-¹³C,d₃-1 (hydrochloride)  |  Efonidipine hydrochloride monoethanolate  |  L-Ascorbic acid sodium salt  |  Taurolithocholic acid-d₄ (sodium)  |  Nilvadipine  |  N-type calcium channel blocker-1  |  Lercanidipine  |  SQ-31765  |  CP-060  |  ISX-9  |  Nisoldipine-d₆  |  Catharanthine  |  Ginsenoside Rd  |  Manidipine dihydrochloride  |  Ziconotide  |  MMK1  |  Ranolazine-d₅  |  Isradipine  |  L-Ascorbic acid-¹³C₆  |  AE0047 Hydrochloride  |  Brompheniramine maleate  |  FPL64176

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物  |  寡核苷酸  |  抗体  |  点击化学

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种*仅有化合物库，我们致力于为*科研客户提供前沿的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药 Patent 收录了MCE客户的科研成果；
•   专业团队跟踪新的制药及生命科学研究进展，为您提供*新的活性化合物；
•   与世界各大制药公司及*科研机构建立了长期的合作。